Biofrontera (NasdaqCM:BFRI) FY Conference Transcript

Summary of Key Points from the Investor Healthcare Summit Company Overview Biofrontera Inc. - Industry: Dermatology - Ticker: BFRI on NASDAQ - Key Product: Ameluz, a drug for photodynamic therapy targeting dermatologic and oncologic indications [2][3] Core Insights and Arguments Product and Market Opportunity - Current Indication: Ameluz is approved for actinic keratosis, representing a market opportunity of approximately $500 million [4][10] - Growth Strategy: Plans to expand the label for Ameluz to include additional indications and body areas beyond the face and scalp [14][15] - Market Dynamics: Currently, only 2% of actinic keratosis treatments utilize photodynamic therapy (PDT), indicating significant growth potential as the market is primarily dominated by cryotherapy [10][11] Financial Performance - Revenue Growth: Biofrontera reported revenues of $37.3 million in 2024, with significant growth anticipated for 2025 [4][18] - Gross Margin Improvement: Following the transfer of Ameluz ownership, gross margins are expected to rise from around 50% to 80%-85% [5][19] - Reimbursement Landscape: Ameluz is well-reimbursed by Medicare and 95% of private payers, enhancing its market adoption [12] Competitive Positioning - Treatment Efficacy: In clinical trials, 91% of patients were fully cleared of actinic keratosis after one or two treatments, with 63% remaining clear after one year [8][9] - Intellectual Property: Strong patent protection for Ameluz, with the longest patent extending to 2043, providing a competitive edge [13] Future Growth Drivers - New Indications: Anticipated FDA approval for basal cell carcinoma treatment by the end of September 2026, and ongoing trials for moderate to severe acne [16][18] - Sales Strategy: Focus on converting customers from cryotherapy to Ameluz and optimizing sales force productivity [17][18] LSL Pharma Group Overview Company Overview - Industry: Specialty Pharmaceuticals - Ticker: LSL on TSXV - Business Segments: Contract manufacturing (CMO), eye care, and OTC products [25] Core Insights and Arguments Business Growth - Revenue Growth: From under CAD 1 million at inception to projected over CAD 60 million in 2026 [25][27] - CMO Segment: Expected to generate CAD 45 million in revenue in 2026, with a diversified client base of 60-70 companies [28][29] Competitive Positioning - Quality and R&D: Known for high-quality products and strong R&D capabilities, leading to low client turnover [29] Future Growth Drivers - Ophthalmic Products: Plans to expand into the U.S. market with FDA approval for ointments and new eye drops expected in Q2 2026 [31][34] - OTC Acquisition: Recent acquisition of Juno OTC aims to enhance product offerings and increase top-line revenue [37] Financial Performance - Profitability Outlook: Projected EBITDA of approximately CAD 4 million on a CAD 30 million top line for 2025, with a focus on increasing margins in the ophthalmic segment [41] Strategic Focus - Integration of Acquisitions: Key challenge for 2026 will be integrating recent acquisitions while maintaining quality and exploring further M&A opportunities [43][44] - Long-term Goals: Aim to reach CAD 100 million in top-line revenue within two years through organic growth and acquisitions [42] Additional Important Insights - Market Dynamics: The U.S. market for ophthalmic products presents significant opportunities due to the lack of generic competition [44] - Investor Confidence: Emphasis on sustainable growth and maintaining a strong balance sheet to create shareholder value [45]